Guardant Health’s CEO Helmy Eltoukhy expects the launch of the company’s new liquid biopsy test, indicated for detecting early-stage colorectal cancer, will be a “big game changer.”
The new liquid biopsy test, Guardant Reveal, is a plasma-only circulating tumor DNA (ctDNA) test indicated for detecting residual and recurrent disease from a whole blood draw. The minimal residue disease test (MRD) does not require patients to undergo tissue-testing and results are available in seven days compared with six to eight weeks for tissue-based testing, Eltoukhy told Medtech Insight. Testing is done at Guardant’s own laboratory, the company said